- Home
- PLRX vs GDL Comparison
PLRX vs GDL Comparison
Compare PLRX & GDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLRX
- GDL
- Stock Information
- Founded
- PLRX 2015
- GDL 2006
- Country
- PLRX United States
- GDL United States
- Employees
- PLRX N/A
- GDL N/A
- Industry
- PLRX Biotechnology: Pharmaceutical Preparations
- GDL Investment Managers
- Sector
- PLRX Health Care
- GDL Finance
- Exchange
- PLRX Nasdaq
- GDL Nasdaq
- Market Cap
- PLRX 93.3M
- GDL 94.9M
- IPO Year
- PLRX 2020
- GDL N/A
- Fundamental
- Price
- PLRX $1.61
- GDL $8.51
- Analyst Decision
- PLRX Hold
- GDL
- Analyst Count
- PLRX 11
- GDL 0
- Target Price
- PLRX $3.79
- GDL N/A
- AVG Volume (30 Days)
- PLRX 973.1K
- GDL 11.2K
- Earning Date
- PLRX 11-06-2025
- GDL 01-01-0001
- Dividend Yield
- PLRX N/A
- GDL 6.02%
- EPS Growth
- PLRX N/A
- GDL N/A
- EPS
- PLRX N/A
- GDL N/A
- Revenue
- PLRX N/A
- GDL N/A
- Revenue This Year
- PLRX N/A
- GDL N/A
- Revenue Next Year
- PLRX N/A
- GDL N/A
- P/E Ratio
- PLRX N/A
- GDL N/A
- Revenue Growth
- PLRX N/A
- GDL N/A
- 52 Week Low
- PLRX $1.10
- GDL $7.65
- 52 Week High
- PLRX $15.88
- GDL $8.13
- Technical
- Relative Strength Index (RSI)
- PLRX 47.40
- GDL 51.31
- Support Level
- PLRX $1.61
- GDL $8.45
- Resistance Level
- PLRX $1.72
- GDL $8.53
- Average True Range (ATR)
- PLRX 0.13
- GDL 0.06
- MACD
- PLRX -0.02
- GDL 0.00
- Stochastic Oscillator
- PLRX 29.00
- GDL 79.41
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
About GDL GDL Fund The of Beneficial Interest
GDL Fund is a diversified closed-end management investment company. Its primary investment objective is to achieve absolute returns in various market conditions without excessive risk of capital. The fund seeks to achieve its objective by investing in merger arbitrage transactions and, to a lesser extent, in corporate reorganizations involving stubs, spin-offs, and liquidations.